PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Double-blind, Double-dummy, Multicenter, Randomized Study of the Efficacy and Tolerability of Valdecoxib 40 mg Versus Rofecoxib 50 mg in Treating the Symptoms of Ankle Sprain
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00657449
- Locations
- 🇧🇷
Instituto Ortopedico de Goiania, Goiania, Goias, Brazil
🇧🇷Grupo Hospitalar Conceiçao, Porto Alegre, RS, Brazil
🇧🇷Hospital Geral do Grajau, São Paulo, SP, Brazil
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
Phase 3
Terminated
- Conditions
- Generalized Anxiety Disorder
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 501
- Registration Number
- NCT00658008
- Locations
- 🇷🇺
Pfizer Investigational Site, Khotkovo, Moscow region, Russian Federation
A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 306
- Registration Number
- NCT00655369
- Locations
- 🇨🇦
Pfizer Investigational Site, Toronto, Ontario, Canada
Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study
Phase 4
Terminated
- Conditions
- ThromboembolismDeep Vein ThrombosisDalteparin
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT00655122
- Locations
- 🇪🇸
Pfizer Investigational Site, Torremolinos, Spain
Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 265
- Registration Number
- NCT00652808
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-05-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 225
- Registration Number
- NCT00652925
- Locations
- 🇸🇪
Pfizer Investigational Site, Stockholm, Sweden
Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery
Phase 3
Completed
- Conditions
- Pain, Post-surgical
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 360
- Registration Number
- NCT00653354
- Locations
- 🇺🇸
Pfizer Investigational Site, Salt Lake City, Utah, United States
A Dose-Ranging Study Of Valdecoxib 5 Mg, 10 Mg, And 20 Mg Once Daily Versus Placebo In Patients With Osteoarthritis Of The Knee (Japan)
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 416
- Registration Number
- NCT00650624
- Locations
- 🇯🇵
Pfizer Investigational Site, Tokyo, Japan
Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554
Phase 1
Completed
- Conditions
- HEPATITIS C (HCV)
- Interventions
- Drug: PF-868554
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2014-01-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00651027
- Locations
- 🇺🇸
Pfizer Investigational Site, Miami, Florida, United States
A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00651287
- Locations
Pfizer Investigational Site
© Copyright 2025. All Rights Reserved by MedPath